<!DOCTYPE html>
<!--[if lt IE 7]>      <html class="no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]-->
<!--[if IE 7]>         <html class="no-js lt-ie9 lt-ie8"> <![endif]-->
<!--[if IE 8]>         <html class="no-js lt-ie9"> <![endif]-->
<!--[if gt IE 8]><!--> <html class="no-js"> <!--<![endif]-->

<head>
	<meta charset="utf-8">
<meta name="author" content="Dove Press">
<meta name="viewport" content="initial-scale=1.0, width=device-width">
<title>The 2-oxoglutarate analog 3-oxoglutarate decreases normoxic hypoxia-in | HP</title>
<meta property="og:title" content="The 2-oxoglutarate analog 3-oxoglutarate decreases normoxic hypoxia-in | HP" />
<meta name="description" content="The 2-oxoglutarate analog 3-oxoglutarate decreases normoxic hypoxia-inducible factor-1&amp;alpha; in cancer cells, induces cell death, and reduces tumor xenograft growth Peppi Koivunen,1 Stuart M Fell,2,3 Wenyun Lu,4 Joshua D Rabinowitz,4 Andrew L Kung,5,6 Susanne Schlisio,2,7&amp;nbsp;1Biocenter Oulu, Faculty of Biochemistry and Molecular Medicine, Oulu Center for Cell-Matrix Research, University of Oulu, Oulu, Finland; 2Ludwig Institute for Cancer Research Ltd, Stockholm, Sweden; 3Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden; 4Department of Chemistry and Integrative Genomics, Princeton University, Princeton, NJ, 5Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, 6Department of Pediatrics, Columbia University Medical Center, New York, NY, USA; 7Department of Microbiology and Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden  Abstract: The cellular response to hypoxia is primarily regulated by the hypoxia-inducible factors (HIFs). HIF-1&amp;alpha; is also a major mediator of tumor physiology, and its abundance is correlated with therapeutic resistance in a broad range of cancers. Accumulation of HIF-1&amp;alpha; under hypoxia is mainly controlled by the oxygen-sensing HIF prolyl 4-hydroxylases (EGLNs, also known as PHDs). Here, we identified a high level of normoxic&amp;nbsp;HIF-1&amp;alpha;&amp;nbsp;protein in various cancer cell lines. EGLNs require oxygen and 2-oxoglutarate for enzymatic activity. We tested the ability of several cell-permeable 2-oxoglutarate analogs to regulate the abundance of&amp;nbsp;HIF-1&amp;alpha;&amp;nbsp;protein. We identified 3-oxoglutarate as a potent regulator of&amp;nbsp;HIF-1&amp;alpha;&amp;nbsp;in normoxic conditions. In contrast to 2-oxoglutarate, 3-oxoglutarate decreased the abundance of&amp;nbsp;HIF-1&amp;alpha;&amp;nbsp;protein in several cancer cell lines in normoxia and diminished&amp;nbsp;HIF-1&amp;alpha;&amp;nbsp;levels independent of EGLN enzymatic activity. Furthermore, we observed that 3-oxoglutarate was detrimental to cancer cell survival. We show that esterified 3-oxoglutarate, in combination with the cancer chemotherapeutic drug vincristine, induces apoptosis and inhibits tumor growth in vitro and in vivo. Our data imply that a novel treatment strategy targeting&amp;nbsp;HIF-1&amp;alpha;&amp;nbsp;in combination with the use of existing cytotoxic agents could serve as potent, future antitumor chemotherapies.  Keywords: cancer, EGLN, HIF, hypoxia, 3-oxoglutarate, prolyl hydroxylase" />
<meta property="og:description" content="The 2-oxoglutarate analog 3-oxoglutarate decreases normoxic hypoxia-inducible factor-1&amp;alpha; in cancer cells, induces cell death, and reduces tumor xenograft growth Peppi Koivunen,1 Stuart M Fell,2,3 Wenyun Lu,4 Joshua D Rabinowitz,4 Andrew L Kung,5,6 Susanne Schlisio,2,7&amp;nbsp;1Biocenter Oulu, Faculty of Biochemistry and Molecular Medicine, Oulu Center for Cell-Matrix Research, University of Oulu, Oulu, Finland; 2Ludwig Institute for Cancer Research Ltd, Stockholm, Sweden; 3Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden; 4Department of Chemistry and Integrative Genomics, Princeton University, Princeton, NJ, 5Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, 6Department of Pediatrics, Columbia University Medical Center, New York, NY, USA; 7Department of Microbiology and Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden  Abstract: The cellular response to hypoxia is primarily regulated by the hypoxia-inducible factors (HIFs). HIF-1&amp;alpha; is also a major mediator of tumor physiology, and its abundance is correlated with therapeutic resistance in a broad range of cancers. Accumulation of HIF-1&amp;alpha; under hypoxia is mainly controlled by the oxygen-sensing HIF prolyl 4-hydroxylases (EGLNs, also known as PHDs). Here, we identified a high level of normoxic&amp;nbsp;HIF-1&amp;alpha;&amp;nbsp;protein in various cancer cell lines. EGLNs require oxygen and 2-oxoglutarate for enzymatic activity. We tested the ability of several cell-permeable 2-oxoglutarate analogs to regulate the abundance of&amp;nbsp;HIF-1&amp;alpha;&amp;nbsp;protein. We identified 3-oxoglutarate as a potent regulator of&amp;nbsp;HIF-1&amp;alpha;&amp;nbsp;in normoxic conditions. In contrast to 2-oxoglutarate, 3-oxoglutarate decreased the abundance of&amp;nbsp;HIF-1&amp;alpha;&amp;nbsp;protein in several cancer cell lines in normoxia and diminished&amp;nbsp;HIF-1&amp;alpha;&amp;nbsp;levels independent of EGLN enzymatic activity. Furthermore, we observed that 3-oxoglutarate was detrimental to cancer cell survival. We show that esterified 3-oxoglutarate, in combination with the cancer chemotherapeutic drug vincristine, induces apoptosis and inhibits tumor growth in vitro and in vivo. Our data imply that a novel treatment strategy targeting&amp;nbsp;HIF-1&amp;alpha;&amp;nbsp;in combination with the use of existing cytotoxic agents could serve as potent, future antitumor chemotherapies.  Keywords: cancer, EGLN, HIF, hypoxia, 3-oxoglutarate, prolyl hydroxylase" />
<meta property="og:image" content="https://www.dovepress.com/assets/img/addon/og_logo.png" />
<meta property="og:type" content="website" />
<link rel="canonical" href="https://www.dovepress.com/the-2-oxoglutarate-analog-3-oxoglutarate-decreases-normoxic-hypoxia-in-peer-reviewed-article-HP" />
<meta property="og:url" content="https://www.dovepress.com/the-2-oxoglutarate-analog-3-oxoglutarate-decreases-normoxic-hypoxia-in-peer-reviewed-article-HP" />
<link itemprop="sameAs" href="https://twitter.com/dovepress">
<link rel="image_src" href="assets/img/addon/favicon.ico" />
<link rel="shortcut icon" type="image/x-icon" href="assets/img/addon/favicon.ico" />
<meta name="citation_title" content="The 2-oxoglutarate analog 3-oxoglutarate decreases normoxic hypoxia-inducible factor-1&amp;alpha; in cancer cells, induces cell death, and reduces tumor xenograft growth">
<meta name="citation_publication_date" content="2016/03/04">
<meta name="citation_journal_title" content="Hypoxia">
<meta name="citation_journal_issn" content="2324-1128">
<meta name="citation_journal_abbrev" content="HP">
<meta name="citation_publisher" content="Dove Press">
<meta name="citation_language" content="English">
<meta name="citation_volume" content="4">
<meta name="citation_firstpage" content="15">
<meta name="citation_lastpage" content="27">
<meta name="citation_doi" content="10.2147/HP.S96366">
<meta name="citation_pdf_url" content="https://www.dovepress.com/getfile.php?fileID=29271">
<meta name="citation_author" content="Peppi Koivunen">
<meta name="citation_author" content="Stuart M Fell">
<meta name="citation_author" content="Wenyun Lu">
<meta name="citation_author" content="Joshua D Rabinowitz">
<meta name="citation_author" content="Andrew L Kung">
<meta name="citation_author" content="Susanne Schlisio">
<link rel="stylesheet" href="cr_data/cache/css_compressed/min.standard.css"  media="all" />
<link rel="stylesheet" href="cr_data/cache/css_compressed/min.standard.articles.print.css"  media="print" />
<link rel="stylesheet" href="cr_data/cache/css_compressed/min.standard.articles.screen.css"  media="screen" />
<!--[if lt IE 9]>
<script src="assets/js/html5shiv.js"></script>
<![endif]-->

<!-- Google Tag Manager -->
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-W2V6CH');</script>
<!-- End Google Tag Manager -->

</head>
<body>
    <!-- Google Tag Manager (noscript) -->
<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-W2V6CH"
height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<!-- End Google Tag Manager (noscript) -->    <div id="modal_wrapper">
        <div id="modal_bg"></div>
        <div id="modal_popup"></div>
    </div>
	<noscript>
	<div id='jswarn'>
	<p>Javascript is currently disabled in your browser. Several features of
	this site will not function whilst javascript is disabled.</p>
	</div>
</noscript>
	<div id="page">
        <div id="mobile-bg">
	<div class="mobile">
		<ul>
			<li><a href="browse_journals.php" id="browse-journals">Browse Journals</a></li>
			<li><a href="why_publish_with_dove.php" id="why-publish">Why Publish With Dove?</a></li>
			<li><a href="editors_in_chief.php" id="editors-in-chief">Editors-in-Chief</a></li>
			<li><a href="author_guidelines.php" id="author-guidelines">Author Guidelines</a></li>
			<li><a href="peer_review_guidelines.php" id="peer-review-guidelines">Peer Review Guidelines</a></li>
			<li><a href="open_outlook.php" id="open-outlook">Open Outlook</a></li>
			<li><a href="blog_post.php" id="blog-post">Blog</a></li>
			<li><a href="#" id="submit-manuscript" class="orange">Submit Manuscript</a></li>
		</ul>
	</div>
</div>
<div class="top_bg group">
	<div class="top group">
		<div class="mobile-nav">
			<a href="#" id="toggle"><img src="assets/img/mobile-icon.png" width="20" height="14" /> Menu</a>
		</div>
		<ul>
			<li><a href="about_dovepress.php">About</a></li>
			<li class="mobile-top"><a href="contact.php" class="contact">Contact</a></li>
			<li><a href="sustainability.php">Sustainability</a></li>
			<li><a href="press_releases.php">Press Releases</a></li>
			<li><a href="testimonials.php">Testimonials</a></li>
			<li><a href="blog_post.php">Blog</a></li>
			<li><a href="fav_author.php">Favored Author Program</a></li>
			<li><a href="permissions.php">Permissions</a></li>
			<li><a href="presubmission_check.php">Pre-Submission</a></li>
			<li class="mobile-top">
									<a href="login.php" class="login"><strong>Login</strong></a>
								</li>
            <li class="mobile-top">
                <a target="_blank" href="http://www.dovepress.com.cn"><img src="assets/img/flags/cn-2.png" alt="Chinese website (中文网站)" title="Chinese website (中文网站)" /></a>
            </li>
		</ul>
	</div>
</div>

<div class="mast_bg group">
	<div class="mast group">
		<div class="logo">
			<a href="index.php" name="page-top"><img src="assets/img/logo.png" width="205" height="43" /></a>
			<p>open access to scientific and medical research</p>	
		</div>
		<!-- /end logo -->
		<div class="search-bg">
			<form method="get" action="search_results.php">
				<input type="text" name="search_word" value="" placeholder="Search Dove Press" class="search" />
				<span style="display: inline-block">
					<input type="submit" value="Search" class="btn-search" id="sitewide-search" />
					<a href="search_advance.php" class="link-search-advanced">Advanced search</a>
				</span>
			</form>
		</div>
		<!-- /end search_bg -->
        	</div>
	<!-- /end mast -->
</div>
<!-- /end mast_bg -->


<nav role="navigation" class="nav_bg group">
	<div class="nav group">
		<ul>
			<li class=""><a href="index.php" >Home</a></li><li class=""><a href="browse_journals.php" >Browse Journals</a></li><li class=""><a href="why_publish_with_dove.php" >Why Dove?</a></li><li class=""><a href="editors_in_chief.php" >Editors-in-Chief</a></li><li class=""><a href="author_guidelines.php" >Author Guidelines</a></li><li class=""><a href="peer_review_guidelines.php" >Peer Review Guidelines</a></li><li class=""><a href="open_outlook.php" >Open Outlook</a></li>		</ul>
	</div>
	<!-- /end nav -->
</nav>
<!-- /end nav_bg -->		<div class="grid_bg group">
			<div class="grid group">
				<aside role="complementary" class="sidebar">
					<section class="box-wrap"><section class="box-ticker"><div class="small-bottom-padding"><h5>Average Article Statistics</h5></div><div class="no-top-padding">
								<div class="journal-counter">
									<h4><span class="ticker-num">2</span><span class="ticker-num">3</span> <span class="ticker-days">Days</span></h4>
								</div>
								<div class="box-ticker-note">*</div>
								<p class="journal-ticker">from submission to first editorial decision.</p>
							</div><div class="no-top-padding">
								<div class="journal-counter">
									<h4><span class="ticker-num">2</span><span class="ticker-num">0</span> <span class="ticker-days">Days</span></h4>
								</div>
								<div class="box-ticker-note">*</div>
								<p class="journal-ticker">from editorial acceptance to publication.</p>
							</div><div class="no-top-padding box-ticker-footnote"><p>*Business days (Mon-Fri)</p></div></section></section><section class="box-wrap">
	<section class="box-ticker">
		<div class="padding">
			<div class="ticker">
				<h4>
					<span class="ticker-num">3</span><span class="ticker-num">3</span><span class="ticker-num">2</span><span class="ticker-num">4</span><span class="ticker-num">6</span>				</h4>
			</div>
			<p>Papers Published</p>
		</div>
	</section>
</section>
<section class="box-wrap">
	<section class="box-none">
		<div class="width-padding">
		<a href="submit_step_1.php" class="manuscript-btn">Submit Manuscript</a>
		</div>
	</section>
	<!-- /end box -->
</section>
<!-- /end box-wrap --><section class="box-wrap">
	<section class="box light-green">
		<div class="padding">
			<h4>Journal Email Alerts</h4>
			<a href="register.php" class="alerts-btn">Signup for Alerts</a>
		</div>
	</section>
	<!-- /end box -->
</section>
<!-- /end box-wrap -->			<section class="box-wrap ">
				<section class="box-bg">
					<div class="padding">
						<h4>About Dove Press</h4>
												<p>Open access peer-reviewed scientific and medical journals.</p>
													<a href="http://www.dovepress.com/about_dovepress.php"  class="std-link">Learn more</a>
												</div>
				</section>
				<!-- /end box-open -->
			</section>
			<!-- /end box-wrap -->
						<section class="box-wrap ">
				<section class="box-bg">
					<div class="padding">
						<h4>Open Access</h4>
													<img src="cr_data/promo_box_image/promo_9.jpg" />
													<p>Dove Medical Press is a member of the OAI.</p>
													<a href="why_publish_with_dove.php?content_id=3045"  class="std-link">Learn more</a>
												</div>
				</section>
				<!-- /end box-open -->
			</section>
			<!-- /end box-wrap -->
						<section class="box-wrap ">
				<section class="box-bg">
					<div class="padding">
						<h4>Reprints</h4>
												<p>Bulk reprints for the pharmaceutical industry.</p>
													<a href="bulk_reprints.php"  class="std-link">Learn more</a>
												</div>
				</section>
				<!-- /end box-open -->
			</section>
			<!-- /end box-wrap -->
						<section class="box-wrap promo-box">
				<section class="box-open">
					<div class="padding">
						<h4>Favored Authors</h4>
												<p>We offer real benefits to our authors, including fast-track processing of papers.</p>
													<a href="fav_author.php"  class="std-link">Learn more</a>
												</div>
				</section>
				<!-- /end box-open -->
			</section>
			<!-- /end box-wrap -->
			<!-- end echoFromCache --><section class="box-wrap">
	<section class="box-open">
		<div class="padding">
			<h5>Social Media</h5>
			<a href="https://www.facebook.com/DoveMedicalPress" class="btn-facebook" id="facebook"></a> &nbsp;
			<a href="https://twitter.com/DovePress" class="btn-twitter" id="twitter"></a> &nbsp;
			<a href="https://www.linkedin.com/company/dove-medical-press" class="btn-linked-in" id="linked-in"></a> &nbsp;
			<a href="https://plus.google.com/103430773410928392958" class="btn-google" id="google"></a> &nbsp;
			<a href="https://www.youtube.com/user/dovepress" class="btn-youtube" id="youtube"></a>
		</div>
	</section>
	<!-- /end box-open -->
</section>
<!-- /end box-wrap --><section class="box-wrap">
	<section class="box-none">
        <iframe src="live_chat.php" width="90%" height="60"></iframe>
	</section>
	<!-- /end box-open -->
</section>
<!-- /end box-wrap -->				</aside>
	
				<div role="main" class="main" id="content">
					<p class="back">Back to <a href="browse_journals.php">Browse Journals</a> &raquo; <a href="hypoxia-journal">Hypoxia</a> &raquo; <a href="hypoxia-archive149-v1053">Volume 4</a></p><div class="tabs-bg group"><div class="tabs-padding group">	<div class="article-labels group">
        <div class="tag  article-tag">Original Research</div>	</div>
	<h1>The 2-oxoglutarate analog 3-oxoglutarate decreases normoxic hypoxia-inducible factor-1&alpha; in cancer cells, induces cell death, and reduces tumor xenograft growth</h1><div class="mobile-social"><a href="https://twitter.com/intent/tweet?text=The+2-oxoglutarate+analog+3-oxoglutarate+decreases+normoxic+hypoxia-in+%7C+HP+%40DovePress&related=DovePress&url=https://www.dovepress.com/the-2-oxoglutarate-analog-3-oxoglutarate-decreases-normoxic-hypoxia-in-peer-reviewed-article-HP" class="btn-twitter btn-page-share" id="twitter" title="share this page on Twitter"></a>&nbsp;<a href="https://www.facebook.com/sharer.php?u=https://www.dovepress.com/the-2-oxoglutarate-analog-3-oxoglutarate-decreases-normoxic-hypoxia-in-peer-reviewed-article-HP&t=The 2-oxoglutarate analog 3-oxoglutarate decreases normoxic hypoxia-in | HP" class="btn-facebook btn-page-share" id="facebook" title="share this page on Facebook"></a>&nbsp;<a href="qr.php?p=https://www.dovepress.com/the-2-oxoglutarate-analog-3-oxoglutarate-decreases-normoxic-hypoxia-in-peer-reviewed-article-HP" class="btn-wechat btn-page-share" id="wechat" title="share this page on WeChat"></a>&nbsp;<a href="https://www.linkedin.com/shareArticle?mini=true&url=https://www.dovepress.com/the-2-oxoglutarate-analog-3-oxoglutarate-decreases-normoxic-hypoxia-in-peer-reviewed-article-HP&title=The+2-oxoglutarate+analog+3-oxoglutarate+decreases+normoxic+hypoxia-in+%7C+HP&source=Dove Press" class="btn-linked-in btn-page-share" title="share this page on Linkedin"></a>&nbsp;<a href="http://del.icio.us/post?url= https://www.dovepress.com/the-2-oxoglutarate-analog-3-oxoglutarate-decreases-normoxic-hypoxia-in-peer-reviewed-article-HP" class="btn-delicious btn-page-share" id="delicious" title="share this page on Delicious"></a>&nbsp;<a href="https://plus.google.com/share?url=https://www.dovepress.com/the-2-oxoglutarate-analog-3-oxoglutarate-decreases-normoxic-hypoxia-in-peer-reviewed-article-HP" class="btn-google btn-page-share" id="google" title="share this page on Google+"></a>&nbsp;<a href="https://www.reddit.com/submit?url=https://www.dovepress.com/the-2-oxoglutarate-analog-3-oxoglutarate-decreases-normoxic-hypoxia-in-peer-reviewed-article-HP" class="btn-reddit btn-page-share" id="reddit" title="share this page on Reddit"></a>&nbsp;<a href="http://www.citeulike.org/posturl?url=https%3A%2F%2Fwww.dovepress.com%2Fthe-2-oxoglutarate-analog-3-oxoglutarate-decreases-normoxic-hypoxia-in-peer-reviewed-article-HP&title=The+2-oxoglutarate+analog+3-oxoglutarate+decreases+normoxic+hypoxia-in+%7C+HP" class="btn-citeulike" id="citeulike" title="share this page on CiteULike"></a>&nbsp;<a href="http://www.mendeley.com/import/?url=https%3A%2F%2Fwww.dovepress.com%2Fthe-2-oxoglutarate-analog-3-oxoglutarate-decreases-normoxic-hypoxia-in-peer-reviewed-article-HP" class="btn-mendeley" id="mendeley" title="share this page on Mendeley"></a>&nbsp;<a href="site_referral.php?article_id=25849" class="btn-email" id="email" title="share this page via Email"></a>&nbsp;</div><div class="tabs print-hide"><a href="https://twitter.com/intent/tweet?text=The+2-oxoglutarate+analog+3-oxoglutarate+decreases+normoxic+hypoxia-in+%7C+HP+%40DovePress&related=DovePress&url=https://www.dovepress.com/the-2-oxoglutarate-analog-3-oxoglutarate-decreases-normoxic-hypoxia-in-peer-reviewed-article-HP" class="btn-twitter btn-page-share" id="twitter" title="share this page on Twitter"></a>&nbsp;<a href="https://www.facebook.com/sharer.php?u=https://www.dovepress.com/the-2-oxoglutarate-analog-3-oxoglutarate-decreases-normoxic-hypoxia-in-peer-reviewed-article-HP&t=The 2-oxoglutarate analog 3-oxoglutarate decreases normoxic hypoxia-in | HP" class="btn-facebook btn-page-share" id="facebook" title="share this page on Facebook"></a>&nbsp;<a href="qr.php?p=https://www.dovepress.com/the-2-oxoglutarate-analog-3-oxoglutarate-decreases-normoxic-hypoxia-in-peer-reviewed-article-HP" class="btn-wechat btn-page-share" id="wechat" title="share this page on WeChat"></a>&nbsp;<a href="https://www.linkedin.com/shareArticle?mini=true&url=https://www.dovepress.com/the-2-oxoglutarate-analog-3-oxoglutarate-decreases-normoxic-hypoxia-in-peer-reviewed-article-HP&title=The+2-oxoglutarate+analog+3-oxoglutarate+decreases+normoxic+hypoxia-in+%7C+HP&source=Dove Press" class="btn-linked-in btn-page-share" title="share this page on Linkedin"></a>&nbsp;<a href="http://del.icio.us/post?url= https://www.dovepress.com/the-2-oxoglutarate-analog-3-oxoglutarate-decreases-normoxic-hypoxia-in-peer-reviewed-article-HP" class="btn-delicious btn-page-share" id="delicious" title="share this page on Delicious"></a>&nbsp;<a href="https://plus.google.com/share?url=https://www.dovepress.com/the-2-oxoglutarate-analog-3-oxoglutarate-decreases-normoxic-hypoxia-in-peer-reviewed-article-HP" class="btn-google btn-page-share" id="google" title="share this page on Google+"></a>&nbsp;<a href="https://www.reddit.com/submit?url=https://www.dovepress.com/the-2-oxoglutarate-analog-3-oxoglutarate-decreases-normoxic-hypoxia-in-peer-reviewed-article-HP" class="btn-reddit btn-page-share" id="reddit" title="share this page on Reddit"></a>&nbsp;<a href="http://www.citeulike.org/posturl?url=https%3A%2F%2Fwww.dovepress.com%2Fthe-2-oxoglutarate-analog-3-oxoglutarate-decreases-normoxic-hypoxia-in-peer-reviewed-article-HP&title=The+2-oxoglutarate+analog+3-oxoglutarate+decreases+normoxic+hypoxia-in+%7C+HP" class="btn-citeulike" id="citeulike" title="share this page on CiteULike"></a>&nbsp;<a href="http://www.mendeley.com/import/?url=https%3A%2F%2Fwww.dovepress.com%2Fthe-2-oxoglutarate-analog-3-oxoglutarate-decreases-normoxic-hypoxia-in-peer-reviewed-article-HP" class="btn-mendeley" id="mendeley" title="share this page on Mendeley"></a>&nbsp;<a href="site_referral.php?article_id=25849" class="btn-email" id="email" title="share this page via Email"></a>&nbsp;<ul><li class="here"><a href="#"  >Abstract</a></li><li class=""><a href="the-2-oxoglutarate-analog-3-oxoglutarate-decreases-normoxic-hypoxia-in-peer-reviewed-fulltext-article-HP"  title="Machine readable">Fulltext</a></li><li class=""><a href="article_metric.php?article_id=25849"  >Metrics</a></li><li class=""><a href="//www.copyright.com/ccc/openurl.do?&issn=2324-1128&WT.mc.id=Dove Medical Press" target="_blank" >Get Permission</a></li></ul></div><div class="tab-content">
	<div class="articles">
		
<div class="intro">
    <div class="padding">				
        <p>
            <strong>Authors</strong> Koivunen P, Fell SM, Lu W, Rabinowitz JD, Kung AL, Schlisio S        </p>
                    <p>
                <strong>Received</strong> <abbr title="These are actual dates the paper was submitted to, accepted for, and published in the journal.">14 September 2015</abbr>
            </p>
            <p>
                <strong>Accepted for publication</strong> 11 December 2015            </p>
                    <p>
            <strong>Published</strong> 4 March 2016
                            <a href="hypoxia-archive149-v1053">Volume 2016:4</a>
                                Pages 15&mdash;27                        </p>

                    <p>
                <strong>DOI</strong> <a href="https://doi.org/10.2147/HP.S96366">https://doi.org/10.2147/HP.S96366</a>
            </p>
                        <p>
                <strong>Checked for plagiarism</strong> Yes
            </p>
                        <p>
                <strong>Review by</strong> <a href="peer_review_guidelines.php">Single-blind</a>
            </p>
                            <p>
                    <strong>Peer reviewers approved by</strong> <a target="_blank" href="public_profile.php?id=288200">Professor Jose Lopez-Barneo</a>
                </p>
                            <p>
                <strong>Peer reviewer comments</strong> 3            </p>
                        <p>
                <strong>Editor who approved publication: </strong>
                                    <a target="_blank" href="public_profile.php?id=289502">Prof. Dr. Doerthe Katschinski</a>
                    
            </p>
                        <div class='altmetric-embed' data-doi='https://doi.org/10.2147/HP.S96366'></div>
                </div>
    <!-- /end padding -->
</div>
<!-- /end intro -->		
		<div class="copy">
			<p>Peppi Koivunen,<sup>1</sup> Stuart M Fell,<sup>2,3</sup> Wenyun Lu,<sup>4</sup> Joshua D Rabinowitz,<sup>4</sup> Andrew L Kung,<sup>5,6</sup> Susanne Schlisio,<sup>2,7</sup><br /><br />&nbsp;<sup>1</sup>Biocenter Oulu, Faculty of Biochemistry and Molecular Medicine, Oulu Center for Cell-Matrix Research, University of Oulu, Oulu, Finland; <sup>2</sup>Ludwig Institute for Cancer Research Ltd, Stockholm, Sweden; <sup>3</sup>Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden; <sup>4</sup>Department of Chemistry and Integrative Genomics, Princeton University, Princeton, NJ, <sup>5</sup>Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, <sup>6</sup>Department of Pediatrics, Columbia University Medical Center, New York, NY, USA; <sup>7</sup>Department of Microbiology and Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden<br /> <br /><strong> Abstract: </strong>The cellular response to hypoxia is primarily regulated by the hypoxia-inducible factors (HIFs). HIF-1&alpha; is also a major mediator of tumor physiology, and its abundance is correlated with therapeutic resistance in a broad range of cancers. Accumulation of HIF-1&alpha; under hypoxia is mainly controlled by the oxygen-sensing HIF prolyl 4-hydroxylases (EGLNs, also known as PHDs). Here, we identified a high level of normoxic&nbsp;HIF-1&alpha;&nbsp;protein in various cancer cell lines. EGLNs require oxygen and 2-oxoglutarate for enzymatic activity. We tested the ability of several cell-permeable 2-oxoglutarate analogs to regulate the abundance of&nbsp;HIF-1&alpha;&nbsp;protein. We identified 3-oxoglutarate as a potent regulator of&nbsp;HIF-1&alpha;&nbsp;in normoxic conditions. In contrast to 2-oxoglutarate, 3-oxoglutarate decreased the abundance of&nbsp;HIF-1&alpha;&nbsp;protein in several cancer cell lines in normoxia and diminished&nbsp;HIF-1&alpha;&nbsp;levels independent of EGLN enzymatic activity. Furthermore, we observed that 3-oxoglutarate was detrimental to cancer cell survival. We show that esterified 3-oxoglutarate, in combination with the cancer chemotherapeutic drug vincristine, induces apoptosis and inhibits tumor growth in vitro and in vivo. Our data imply that a novel treatment strategy targeting&nbsp;HIF-1&alpha;&nbsp;in combination with the use of existing cytotoxic agents could serve as potent, future antitumor chemotherapies.<br /> <br /><strong> Keywords:</strong> cancer, EGLN, HIF, hypoxia, 3-oxoglutarate, prolyl hydroxylase<br /></p>				<p class="article-cc-license">
					<img alt="Creative Commons License" style="border-width:0" src="//i.creativecommons.org/l/by-nc/3.0/us/88x31.png" />
					This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <a target="_blank"  href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</a> and incorporate the <a target="_blank" rel="license" href="//creativecommons.org/licenses/by-nc/3.0/">Creative Commons Attribution - Non Commercial (unported, v3.0) License</a>.

					By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of <a target="_blank"  xmlns:cc="//creativecommons.org/ns#" href="https://www.dovepress.com/terms.php" rel="cc:morePermissions">our Terms</a>.
				</p>
				<a class="download-btn print-hide" href="getfile.php?fileID=29271" id="download-pdf">Download Article <span>[PDF]</span></a>&nbsp;				<a class="download-btn print-hide" href="the-2-oxoglutarate-analog-3-oxoglutarate-decreases-normoxic-hypoxia-in-peer-reviewed-fulltext-article-HP" id="view-full-text">View Full Text <span>[HTML]</span><span class="text_machine">[Machine readable]</span></a>
								<p>&nbsp;</p>
				<script src="//api.growkudos.com/widgets/article/10.2147/HP.S96366"></script>
						</div>
		<!-- /end copy -->
	</div>
	<!-- /end articles -->
</div>
<!-- /end tab-content -->
</div></div><div class="categories-bg group"><div class="tabs-padding group"><h2>Readers of this article also read:</h2>
			
<div class="tab-content">
		<div class="tab-item">
        <div class="article-labels group">
    <div class="tag  article-tag">Review</div><img src="assets/img/article_icons/video.png" title="Video" class="article-icon"/></div>		<h3>
			<a href="erythropoietin-and-the-use-of-a-transgenic-model-of-erythropoietin-def-peer-reviewed-article-HP-recommendation1">Erythropoietin and the use of a transgenic model of erythropoietin-deficient mice</a>
		</h3>
					<div class="tab-item-figure video-placeholder">
				<div class="tab-item-video">
					<img src="assets/img/video_100.png" />
				</div>
				<img src="//img.youtube.com/vi/v6FpNxgeLxM/1.jpg" width="120" />
			</div>
					
		<p>Pichon A, Jeton F, El Hasnaoui-Saadani R, Hagström L, Launay T, Beaudry M, Marchant D, Quidu P, Macarlupu JL, Favret F, Richalet JP, Voituron N</p>
		<p class="journal">
			<a href="hypoxia-journal">Hypoxia</a> <a href="hypoxia-archive149-v1053">2016</a>, 4:29-39		</p>
		<p class="journal">Published Date: <strong>7 April 2016</strong></p>
	</div>
	<!-- /end tab-item -->
		<div class="tab-item">
        <div class="article-labels group">
    <div class="tag  article-tag">Original Research</div></div>		<h3>
			<a href="apoptosis-inducing-ability-of-silver-decorated-highly-reduced-graphene-peer-reviewed-article-IJN-recommendation1">Apoptosis inducing ability of silver decorated highly reduced graphene oxide nanocomposites in A549 lung cancer</a>
		</h3>
				
		<p>Khan M, Khan M, Al-Marri AH, Al-Warthan A, Alkhathlan HZ, Siddiqui MR, Nayak VL, Kamal A, Adil SF</p>
		<p class="journal">
			<a href="international-journal-of-nanomedicine-journal">International Journal of Nanomedicine</a> <a href="international-journal-of-nanomedicine-archive5-v998">2016</a>, 11:873-883		</p>
		<p class="journal">Published Date: <strong>7 March 2016</strong></p>
	</div>
	<!-- /end tab-item -->
		<div class="tab-item">
        <div class="article-labels group">
    <div class="tag  article-tag">Original Research</div></div>		<h3>
			<a href="copd-assessment-test-and-severity-of-airflow-limitation-in-patients-wi-peer-reviewed-article-COPD-recommendation1">COPD assessment test and severity of airflow limitation in patients with asthma, COPD, and asthma&ndash;COPD overlap syndrome</a>
		</h3>
				
		<p>Kurashima K, Takaku Y, Ohta C, Takayanagi N, Yanagisawa T,  Sugita Y</p>
		<p class="journal">
			<a href="international-journal-of-chronic-obstructive-pulmonary-disease-journal">International Journal of Chronic Obstructive Pulmonary Disease</a> <a href="international-journal-of-chronic-obstructive-pulmonary-disease-archive6-v997">2016</a>, 11:479-487		</p>
		<p class="journal">Published Date: <strong>4 March 2016</strong></p>
	</div>
	<!-- /end tab-item -->
		<div class="tab-item">
        <div class="article-labels group">
    <div class="tag  article-tag">Original Research</div></div>		<h3>
			<a href="fifteen-days-of-3200-m-simulated-hypoxia-marginally-regulates-markers--peer-reviewed-article-HP-recommendation1">Fifteen days of 3,200 m simulated hypoxia marginally regulates markers for protein synthesis and degradation in human skeletal muscle</a>
		</h3>
				
		<p>D&rsquo;Hulst G, Ferri A, Naslain D, Bertrand L, Horman S, Francaux M, Bishop DJ, Deldicque L</p>
		<p class="journal">
			<a href="hypoxia-journal">Hypoxia</a> <a href="hypoxia-archive149-v1053">2016</a>, 4:1-14		</p>
		<p class="journal">Published Date: <strong>3 March 2016</strong></p>
	</div>
	<!-- /end tab-item -->
		<div class="tab-item">
        <div class="article-labels group">
    <div class="tag  article-tag">Short Report</div></div>		<h3>
			<a href="hypoxia-from-basic-mechanisms-to-therapeutics-ndash-a-meeting-report-o-peer-reviewed-article-HP-recommendation1">Hypoxia: from basic mechanisms to therapeutics &ndash; a meeting report on the Keystone and HypoxiaNet Symposium</a>
		</h3>
				
		<p>Nolan KA, Scholz CC</p>
		<p class="journal">
			<a href="hypoxia-journal">Hypoxia</a> <a href="hypoxia-archive149-v920">2015</a>, 3:67-72		</p>
		<p class="journal">Published Date: <strong>23 October 2015</strong></p>
	</div>
	<!-- /end tab-item -->
		<div class="tab-item">
        <div class="article-labels group">
    <div class="tag  article-tag">Original Research</div></div>		<h3>
			<a href="induction-of-long-noncoding-rna-malat1-in-hypoxic-mice-peer-reviewed-article-HP-recommendation1">Induction of long noncoding RNA MALAT1 in hypoxic mice</a>
		</h3>
				
		<p>Lelli A, Nolan KA, Santambrogio S, Gonçalves AF, Schönenberger MJ, Guinot A, Frew IJ, Marti HH, Hoogewijs D, Wenger RH</p>
		<p class="journal">
			<a href="hypoxia-journal">Hypoxia</a> <a href="hypoxia-archive149-v920">2015</a>, 3:45-52		</p>
		<p class="journal">Published Date: <strong>8 October 2015</strong></p>
	</div>
	<!-- /end tab-item -->
		<div class="tab-item">
        <div class="article-labels group">
    <div class="tag  article-tag">Review</div></div>		<h3>
			<a href="frequently-asked-questions-in-hypoxia-research-peer-reviewed-article-HP-recommendation1">Frequently asked questions in hypoxia research</a>
		</h3>
				
		<p>Wenger RH, Kurtcuoglu V, Scholz CC, Marti HH, Hoogewijs D</p>
		<p class="journal">
			<a href="hypoxia-journal">Hypoxia</a> <a href="hypoxia-archive149-v920">2015</a>, 3:35-43		</p>
		<p class="journal">Published Date: <strong>18 September 2015</strong></p>
	</div>
	<!-- /end tab-item -->
		<div class="tab-item">
        <div class="article-labels group">
    <div class="tag  article-tag">Review</div><img src="assets/img/article_icons/highly-accessed.png" title="Highly-accessed" class="article-icon"/></div>		<h3>
			<a href="complex-role-of-hif-in-cancer-the-known-the-unknown-and-the-unexpected-peer-reviewed-article-HP-recommendation1">Complex role of HIF in cancer: the known, the unknown, and the unexpected</a>
		</h3>
				
		<p>Tiburcio PD, Choi H, Huang LE</p>
		<p class="journal">
			<a href="hypoxia-journal">Hypoxia</a> <a href="hypoxia-archive149-v817">2014</a>, 2:59-70		</p>
		<p class="journal">Published Date: <strong>18 June 2014</strong></p>
	</div>
	<!-- /end tab-item -->
		<div class="tab-item">
        <div class="article-labels group">
    <div class="tag  article-tag">Review</div><img src="assets/img/article_icons/highly-accessed.png" title="Highly-accessed" class="article-icon"/></div>		<h3>
			<a href="ovarian-cancer-emerging-molecular-targeted-therapies-peer-reviewed-article-BTT-recommendation1">Ovarian cancer: emerging molecular-targeted therapies</a>
		</h3>
				
		<p>Sourbier C</p>
		<p class="journal">
			<a href="biologics-targets-and-therapy-journal">Biologics: Targets and Therapy</a> <a href="biologics-targets-and-therapy-archive8-v510">2012</a>, 6:147-154		</p>
		<p class="journal">Published Date: <strong>20 June 2012</strong></p>
	</div>
	<!-- /end tab-item -->
		<div class="tab-item">
        <div class="article-labels group">
    <div class="tag  article-tag">Case report</div><img src="assets/img/article_icons/highly-accessed.png" title="Highly-accessed" class="article-icon"/></div>		<h3>
			<a href="crystallization-after-intravitreal-ganciclovir-injection-peer-reviewed-article-OPTH-recommendation1">Crystallization after intravitreal ganciclovir injection</a>
		</h3>
				
		<p>Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant</p>
		<p class="journal">
			<a href="clinical-ophthalmology-journal">Clinical Ophthalmology</a> <a href="clinical-ophthalmology-archive9-v221">2010</a>, 4:709-711		</p>
		<p class="journal">Published Date: <strong>14 July 2010</strong></p>
	</div>
	<!-- /end tab-item -->
	</div>
<!-- /end tabs-content --></div></div>				</div>
				<!-- /end main -->
			</div>
			<!-- /end grid -->
		</div>
		<!-- /end grid_bg -->
	
		<div class="footer-nav-bg group">
	<div class="footer-nav group">
		<div class="footer-desktop-nav">
			<p>
				<a href="contact.php">Contact Us</a> &nbsp;
				<span>&bull;</span>&nbsp; <a href="privacy.php">Privacy Policy</a> &nbsp;
				<span>&bull;</span>&nbsp; <a href="partners.php">Associations &amp; Partners</a> &nbsp;
				<span>&bull;</span>&nbsp; <a href="testimonials.php">Testimonials</a> &nbsp;
				<span>&bull;</span>&nbsp; <a href="sitemap.php">Sitemap</a> &nbsp;
				<span>&bull;</span>&nbsp; <a href="terms.php">Terms &amp; Conditions</a> &nbsp;
				<span>&bull;</span>&nbsp; <a href="site_referral.php">Recommend this site</a>
				<span>&bull;</span>&nbsp; <a href="#page-top">Top</a>
			</p>
		</div>
		<div class="footer-mobile-nav">
			<p><a href="contact.php">Contact Us</a> &nbsp;<span>&bull;</span>&nbsp; <a href="privacy.php">Privacy Policy</a></p>
		</div>
	</div>
	<!-- /end footer-nav -->
</div>
<!-- /end footer-nav-bg --><footer role="contentinfo" class="footer_bg group">
	<div class="footer group">
		<p>
			<strong>&copy; Copyright 2017</strong> &nbsp;<span>&bull;</span>&nbsp; <strong>Dove Press Ltd</strong> &nbsp;
							<span>&bull;</span>&nbsp; Website development by maffey.com
							<span>&bull;</span>&nbsp; Web Design by <a href="http://www.adhesion.co.nz" title="Adhesion Website Design">Adhesion</a>
		</p>
		<p class="small">The opinions expressed in all articles published here are those of the specific author(s), and do not necessarily reflect the views of Dove Medical Press Ltd or any of its employees.</p>
	</div>
	<!-- /end footer -->
	<br clear="all" />
</footer>
<!-- /end footer_bg -->	</div>
	<!-- /end #page -->
	
	<script type='text/javascript' src='assets/js/jquery-1.10.2.min.js'></script>
<script type='text/javascript' src='assets/js/jquery-ui-1.10.4.custom.min.js'></script>
<script type='text/javascript' src='assets/js/addon/jquery.formtools.js'></script>
<script type='text/javascript' src='assets/js/addon/jquery.popupBox.min.js'></script>
<script type='text/javascript' src='assets/js/jquery.news_ticker.min.js'></script>
<script type='text/javascript' src='assets/js/jquery.fitvids.js'></script>

<span id='javascript-insert-point'></span>

<script type='text/javascript'>
function addJS(url){
	var insertPoint = document.getElementById('javascript-insert-point');
	var element = document.createElement('script');
	element.src = url;
	insertPoint.appendChild(element);
}

function downloadJSAtOnload(){
	addJS('assets/js/main.js');
	addJS('assets/js/addon/addon_v2.js');
	addJS('assets/js/img-sizer.js');
	addJS('https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js');
}

if (window.addEventListener) {
	window.addEventListener('load', downloadJSAtOnload, false);
} else if (window.attachEvent) {
	window.attachEvent('onload', downloadJSAtOnload);
} else {
	window.onload = downloadJSAtOnload;
}

</script>
</body>
</html>